CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 2599575
• 负责人: MARK R. GREEN
• 金额: $ 8.41万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-04-13 至 2001-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2599575
• 关键词: AIDS related neoplasm /cancer; aging; antineoplastics; bone marrow transplantation; breast neoplasms; cancer prevention; cancer registry /resource; carmustine; chemoprevention; cis platinum compound; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; finasteride; fluorouracil; gastrointestinal neoplasms; health care cost /financing; hormone therapy; human genetic material tag; human subject; human therapy evaluation; interleukin 2; leucovorin; leukemia; lymphoma; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; oncology nursing; paclitaxel; pathology; prostate neoplasms; psychology; quality of life; respiratory neoplasm; tamoxifen; tissue resource /registry; weight loss

DESCRIPTION (adapted from the applicant's abstract): This grant application is submitted in support of the CALGB program at the Medical University of South Carolina (MUSC). MUSC has been a main member of CALGB only since July 1995. Yet already the Group Vice Chair, the Vice Chair of the CALGB Radiation Oncology Committee, the Chair of the CALGB Respiratory Committee, one phase III protocol chair, and four study co-chairs are MUSC faculty participants. Active MUSC programs in Experimental Therapeutics, Molecular Oncology, and Cancer Prevention and Control are involved in research activities of direct significance for CALGB based clinical and correlative projects to be proposed to the Group during the grant cycle covered by this application. Accrual to CALGB trials has been designated as the top institutional clinical trials priority by the Cancer Center Director at MUSC. A new CALGB affiliate relationship for the Ralph H. Johnson VA Medical Center in Charleston is being developed as of the Summer of 1997. This will contribute substantially to increased institutional accrual. Minority accrual at MUSC has always been more than double the CALGB average. It has ranged from a low of 25 percent in 1993 (when MUSC participated in CALGB as a Bowman Gray affiliate) to 36 percent in 1995. MUSC plans to participate in the NCI Minority accrual Initiative Program submitted as part of the CALGB Chairman's Central Office Grant. This initiative program and new programs between the Hollings Cancer Center at MUSC and the Charleston minority community, described in this application, should foster additional minority accrual. A CALGB audit at MUSC in September of 1996 was rated as excellent. The Medical University of South Carolina is an effective new Main Member in the Cancer and Leukemia Group B that is in a strong position to make important scientific, administrative, and accrual contribution to the Group during the five year period covered by this grant request.

描述（改编自申请人的摘要）：本拨款申请 提交是为了支持医科大学的 CALGB 项目 南卡罗来纳州（MUSC）。 MUSC 自 7 月起才成为 CALGB 的主要成员 1995年，已担任集团副主席、CALGB副主席 放射肿瘤学委员会，CALGB呼吸委员会主席， 一名第三阶段方案主席和四名研究联合主席是 MUSC 教师 参与者。 活跃的 MUSC 实验治疗学、分子学项目 肿瘤学、癌症预防与控制参与研究 对基于 CALGB 的临床和相关性具有直接意义的活动 在本拨款周期内向集团提出的项目 应用。 CALGB 试验的应计被指定为顶级 癌症中心主任优先进行机构临床试验 MUSC。 与 Ralph H. Johnson VA 建立新的 CALGB 附属关系 查尔斯顿医疗中心于 1997 年夏季开始开发。 这将大大有助于增加机构应计收益。 MUSC 的少数族裔应计额始终是 CALGB 平均水平的两倍以上。 1993 年（当时 MUSC 参与了 CALGB 作为 Bowman Gray 的附属公司）在 1995 年增至 36%。 MUSC 计划 参与作为一部分提交的 NCI 少数族裔应计计划 CALGB 主席中央办公室拨款。 该倡议计划和 MUSC 霍林斯癌症中心和查尔斯顿癌症中心之间的新项目 本申请中描述的少数群体社区应培养更多 少数应计。 1996 年 9 月 MUSC 的 CALGB 审核被评为 出色的。 南卡罗来纳医科大学是一所有效的新大学 处于强势地位的癌症和白血病 B 组主要成员 为科学、行政和权责发生制做出重要贡献 集团在本拨款申请涵盖的五年期间内。